Danaher returns a key business to growth, and we’re raising our stock rating back to buy
Published Tue, Oct 22 20243:17 PM EDT Zev Fima@zevfima In this photo illustration, a Danaher Corporation logo seen displayed on a tablet. Igor Golovnov | SOPA Images | Lightrocket | Getty Images Danaher shares declined Tuesday despite the life sciences company returning its key bioprocessing business to growth in the third quarter. More In Analysis…